Ankr Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco AI that virtualizes clinic front desk, medical assistant, and scribe functions for on-demand virtual clinics; YC-backed at $2.3M revenue with EHR integration generating $1M new revenue for average clinic.
About
Ankr Health is a San Francisco-based healthcare technology company using generative AI to virtualize clinic infrastructure — automating front desk operations, medical assistant workflows, and clinical documentation (AI scribe functions) that enable physicians to launch on-demand virtual and hybrid clinics without the full overhead of physical clinic staff. Founded in 2022 and backed by Y Combinator with $500,000 raised from MedTech Innovator, WorldQuant Ventures, and YC, Ankr Health generated $2.3 million in revenue in 2024 with a 15-person team, with integration across all major EHR systems (Epic, Cerner, athenahealth) and a reported $1 million in new annual revenue generated for average clinic customers.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.